How ophthalmic play Trefoil plans to deploy $28M series A

With $28 million in series A funding, Trefoil plans to submit an IND in early 2020 and complete a Phase IIa proof-of-concept trial of its lead product, TTHX1114, for corneal endothelial dystrophies including Fuchs dystrophy.

Bios Partners led the oversubscribed financing. Fellow new investors Access Biotechnology and FemHealth Ventures as well as existing investors Hatteras Venture Partners, Aju IB Investment, Correlation Ventures, ExSight Ventures, InFocus Capital Partners and an undisclosed individual investor also participated...